Who are olanzapine therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Risperidone high dose, ziprasidone or olanzapine, Perospirone hydrochloride tablets, Aripiprazole; Quetiapine, Risperidone tablets, Intramuscular olanzapine, aripiprazole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olanzapine-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

olanzapine therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

olanzapine therapy (olanzapine therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry.

marketed Atypical antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

olanzapine therapy (olanzapine therapy) — Eli Lilly and Company. Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
olanzapine therapy TARGET	olanzapine therapy	Eli Lilly and Company	marketed	Atypical antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor
Risperidone high dose	Risperidone high dose	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	marketed	Atypical antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor
ziprasidone or olanzapine	ziprasidone or olanzapine	Medical University of Vienna	marketed	Atypical antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor
Perospirone hydrochloride tablets	Perospirone hydrochloride tablets	Shanghai Mental Health Center	marketed	Atypical antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor
Aripiprazole; Quetiapine	Aripiprazole; Quetiapine	Taichung Veterans General Hospital	marketed	Atypical antipsychotic combination	Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor
Risperidone tablets	Risperidone tablets	Sumitomo Pharma (Suzhou) Co., Ltd.	marketed	Atypical antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor
Intramuscular olanzapine, aripiprazole	Intramuscular olanzapine, aripiprazole	Veterans Medical Research Foundation	marketed	Atypical antipsychotic	Dopamine D2 receptor; serotonin 5-HT2A receptor (olanzapine); dopamine D2 partial agonist (aripiprazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

Shanghai Mental Health Center · 10 drugs in this class
AstraZeneca · 6 drugs in this class
Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
Eli Lilly and Company · 4 drugs in this class
Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
Medical University of Vienna · 2 drugs in this class
Organon and Co · 2 drugs in this class
Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
H. Lundbeck A/S · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). olanzapine therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/olanzapine-therapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing